Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

3SBio to Market Japanese Pruritis Treatment in China

publication date: Jan 18, 2018

3SBio of Shenyang in-licensed China rights to a pruritis (itching) treatment developed by Japan's Toray Industries. TRK-820 is a highly selective opioid receptor agonist that is intended to treat the itching that accompanies chronic liver disease and peritoneal dialysis. 3SBio will commercialize the oral disintegration formulation of the drug to facilitate dosing in patients who have difficulty swallowing. The company will make upfront and milestone payments to Toray, though no details were disclosed. More details....

Stock Symbol: (HK: 1530)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.